HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Terminated trial tests new drug duo for tough breast cancers
Disease control TerminatedThis early-phase study aimed to find a safe dose of a new drug, infigratinib, when combined with the established hormone therapy tamoxifen. It was for people with advanced breast cancer that is hormone-sensitive, HER2-negative, and has specific genetic changes (FGFR-altered). The…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Disease control
Last updated Apr 04, 2026 00:50 UTC
-
Experimental drug tested for Tough-to-Treat cancers
Disease control TerminatedThis study tested an experimental drug called VLS-101 (zilovertamab vedotin) in 102 people with advanced solid tumors that had spread and stopped responding to previous treatments. The trial aimed to see if the drug could shrink tumors and was safe for cancers including breast, l…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New cancer drug trial halted early
Disease control TerminatedThis early-stage study aimed to test the safety and find the right dose of a new drug called BLU-222 for people with advanced solid tumors that have stopped responding to standard treatments. It involved about 50 patients with cancers like breast, ovarian, and gastric cancer. The…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:31 UTC
-
Radioactive bullet targets advanced cancers in early trial
Disease control TerminatedThis early-stage study tested a new radioactive drug designed to target and destroy advanced solid tumors. It involved 78 patients with various cancers who had run out of standard treatment options. The main goals were to check the treatment's safety, find the right dose, and see…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Fusion Pharmaceuticals Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC